TrialClinical pharmacology and therapeutics2022

OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.

Mahdi Saghari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.